Abstract: OBJECTIVE To investigate the effect of Qili Qiangxin capsule combined with sacubitril/valsartan on cardiac function in patients with chronic heart failure(CHF). METHODS One hundred and two patients with CHF were randomly divided into two groups:sacubitril/valsartan group(control group) and Qili Qiangxin capsule combined with sacubitril/valsartan group(observation group). Sacubitril/valsartan and sacubitril/valsartan combined with Qili Qiangxin capsule were given to the patients for six months respectively. The apparent efficiency, effective rate and left ventricular end-diastolic diameter(LVEDD), left ventricular end-systolic diameter(LVESD), left ventricular ejection fraction(LVEF), cardiac output(CO), NYHA II improvement rate, N-terminalpro-brain natriuretic peptide(NT-proBNP) and changes of 6-min walk test(6-MWT) were observed. RESULTS After 6 months of treatment, LVESD and LVEDD in both groups were significantly lower than those before treatment(P<0.05), LVEF and CO were significantly higher than those before treatment(P<0.05), but after 6 months of treatment, there was no significant difference between the two group. The significant efficiency and NHYA II level in observation group were significantly higher than those in control group(P<0.05). NT-proBNP in 8 and 12 weeks after treatment was significantly lower than that before treatment(P<0.05). 6-MWT distance was significantly higher than that before treatment(P<0.05), there was no significant difference between the two groups. NT-proBNP in 6 months after treatment was significantly lower than that in the control group(P<0.05), and 6-MWT distance was significantly higher than that in the control group(P<0.05). CONCLUSION Sacubitril/valsartan combined with Qili Qiangxin capsule can further improve the NYHA classification and 6-MWT distance of CHF patients.